Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idetrexed - Algok Bio

Next Previous
Drug Profile

Idetrexed - Algok Bio

Alternative Names: BGC-945; BTG-945; CT-900; ONX-0801; ONX-0901

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Institute of Cancer Research
  • Developer Onyx Pharmaceuticals; Royal Marsden NHS Foundation Trust; The Institute of Cancer Research
  • Class Antineoplastics; Cyclopentanes; Glutamates; Quinazolines; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Second-line therapy or greater, Treatment-resistant, In adults) in United Kingdom (IV, Infusion)
  • 16 May 2025 Institute of Cancer Research in collaboration with Algok Bio plans a phase I/Ib trial for Ovarian Cancer (Combination therapy, Late stage disease, First line therapy) in United Kingdom (IV), in May 2025 (NCT06976892)
  • 04 May 2023 Idetrexed is still in phase I trials for solid tumors in UK

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top